Phosphodiesterase type 5 inhibitors as a treatment for erectile dysfunction: Current information and new horizons
| Autor: | James E. Ferguson, Culley C. Carson |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
FDA
USA Food and Drug Administration Sildenafil Urology Review Avanafil Pharmacology IIEF International Index of Erectile Function chemistry.chemical_compound GTP guanosine triphosphate RCT randomised controlled trial Medicine Erectile dysfunction ED erectile dysfunction sGC soluble guanylyl cyclase NO nitric oxide Tmax time to Cmax Udenafil business.industry Penile disorders medicine.disease Tadalafil SHIM Sexual Health Inventory in Men Tolerability chemistry PDE5(i) phosphodiesterase type 5 (inhibitors) Vardenafil cGMP-specific phosphodiesterase type 5 cGMP cyclic guanosine monophosphate Cmax maximum serum concentration business Phosphodiesterase type 5 inhibitors medicine.drug |
| Zdroj: | Arab Journal of Urology |
| ISSN: | 2090-598X |
| DOI: | 10.1016/j.aju.2013.07.009 |
| Popis: | Introduction Over the past 15 years, the discovery and development of oral medications that selectively inhibit the enzyme phosphodiesterase type 5 (PDE5) have revolutionised the treatment of erectile dysfunction (ED). Currently, three PDE5 inhibitors are widely available clinically, i.e., sildenafil, vardenafil and tadalafil. New PDE5 inhibitors, including avanafil and udenafil, are now in clinical use in a few countries, and other compounds are under development. Methods We describe the current use and future direction of PDE5 inhibitors in the treatment of ED. Results and conclusion Each PDE5 inhibitor has an excellent and comparable efficacy and tolerability. These drugs are highly effective for ED of various causes, and are effective in preventing ED after radical prostatectomy. However, whilst being at least 60% effective, PDE5 inhibitors are still ineffective in at least 30% of patients, prompting current research into other pharmacological targets for ED. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|